Proventa’s Weekly Round-up – 7/10/19

October 7, 2019
In ,

Feeling short of breath? Then you’re probably J&J’s CEO, after the company was forced to settle its part in the ongoing opioid battle with two Ohio counties for $20.4 million. Either way you’re in luck, as Novartis’ phase 3 trial of asthma combo QMF149 in patients has met its primary endpoint, and GSK announces it aims for its asthma triple therapy to receive FDA approval in the near future.

Seriously though, maybe get that breathing problem checked out.

JOHNSON & JOHNSON SETTLES IN OPIOID CASE – Pharma giant J&J has paid two Ohio counties a total of $20.4 million to avoid a trial over its role in fuelling opioid addictions in the state. This follows a recent landmark ruling for J&J to pay Oklahoma $572 million over the same issue. The Ohio deal is not an admission of liability for the accusation.

TRUMP: PHARMA COULD BE BEHIND IMPEACHMENT CALLS – President Trump has accused pharmaceutical companies of acting against him in the recent impeachment scandal, in which the President is suggested to have incited Ukraine and China to investigate rival Joe Biden and his son. No evidence was offered with these claims.

KEYTRUDA TO LEAD DRUG SALES BY 2023 – Merck’s cancer immunotherapy blockbuster Keytruda is set to top the list of best-selling drugs by annual revenue by 2023, forecasts have found, smashing records held by previous incumbent Humira. The PD-1 drug is set to bring in more than $22.2 billion by 2025. It is followed by BMS and Pfizer’s Eliquis, which is set to return $18.7 billion by 2025.

In other news:


Novartis teams up with Microsoft to ‘transform medicine’ with AI

Clinical Trials

Novartis meets primary endpoint for phase 3 trial of QMF149 asthma drug 


GSK and Innoviva file FDA dossier to have asthma triple therapy drug approved 

GSK announces new $139 million plant to produce Benlysta

That’s all for this week. See you next Friday.

Joshua Neil

Editor, Proventa International